Once-feared diseases continue to wreak havoc in the shadows. Tuberculosis, which many imagine confined to history books, nevertheless clings to the fragilities of the present. Neither forgotten nor defeated, it resists traditional treatments and adapts to medical strategies. It is precisely this resistance that is pushing researchers today to reinvent the therapeutic approach. A new avenue is opening up, driven by a promising molecule that could redefine the treatment of this scourge on a global scale.
A disease that we thought was dormant
Long relegated to the past, tuberculosis nevertheless remains the deadliest infectious disease in the world. In 2022, the World Health Organization recorded more than 10 million cases and 1.3 million deaths. Although current treatments exist, their effectiveness is decreasing in the face of the emergence of resistant strains, particularly in Asia and Africa. The protocols are long, demanding, and often poorly followed, which favors the persistence of the bacillus Mycobacterium tuberculosis.
The danger no longer lies in a simple return of the disease. In reality, the real risk is that of a chronic, silent form, rooted in already weakened areas. This is why the TB Drug Accelerator program, supported by the Gates Foundation, has been relaunched. It made it possible to mobilize teams from Texas A&M AgriLife Research, but also from the Calibr-Skaggs Institute for Innovative Medicines. Together, these researchers seek to open new therapeutic avenues.
A molecular process with surgical precision
Their discovery is based on CMX410, a molecule designed to target a key enzyme in the bacteria: polyketide synthase 13. This enzyme participates in the production of the protective wall of the germ. By blocking it, CMX410 deprives tuberculosis of its vital defense.
This locking is carried out using a so-called “click” chemistry process, developed by Barry Sharpless, two-time Nobel Prize winner. This process allows the molecule to be attached to its target enzyme like a puzzle piece, without affecting the surrounding cells. This level of selectivity makes the approach as effective as it is safe.
The study published in Nature specifies that CMX410 acts by irreversible binding, directly neutralizing the active site of the enzyme. This unique mechanism then prevents the bacteria from developing resistance. In tests carried out on 66 strains, including multi-resistant forms isolated from patients, the results were consistent. The molecule effectively paralyzes bacterial growth.
What this TB treatment means for global health
The team led by James Sacchettini also demonstrated that the molecule can be combined safely with other antibiotics used against tuberculosis. Better yet, it causes no side effects in animal models, even at high doses.
This specificity opens the way to shorter, better tolerated and potentially more effective treatments. Furthermore, the molecule acts on a target never before exploited, which reinforces its interest in strategies to circumvent resistance.
As SciTechDaily points out, this approach marks a turning point in the fight against resistant infectious diseases. The development of CMX410 is not limited to tuberculosis. It inaugurates a new generation of smarter antibiotics, capable of hitting hard without unbalancing the body.
While the world is still trying to anticipate the next pandemic, one truth persists. Some old threats remained active, without having been completely eradicated. However, this recent advance suggests a possible victory. It shows that it is never too late to win forgotten battles.
With an unwavering passion for local news, Christopher leads our editorial team with integrity and dedication. With over 20 years’ experience, he is the backbone of Wouldsayso, ensuring that we stay true to our mission to inform.
